Enterprise Value

486M

Cash

471.2M

Avg Qtr Burn

-54.73M

Short % of Float

44.19%

Insider Ownership

29.16%

Institutional Own.

78.32%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ALLO-501A (CD19) Details
Non-Hodgkin lymphoma, Cancer, Diffuse large B cell lymphoma

Phase 3

Initiation

ALLO-316 (CD70) Details
Solid tumor/s, Renal cell carcinoma, Cancer

Phase 1

Data readout

ALLO-501A (CD19) Details
Non-Hodgkin lymphoma, Cancer, Diffuse large B cell lymphoma

Phase 1

Data readout

ALLO-605 (BCMA) Details
Cancer, Multiple myeloma

Phase 1

Update

ALLO-715 (BCMA) Details
Cancer, Multiple myeloma

Phase 1

Update

ALLO-647 (Anti-CD52 mAb) Details
Multiple myeloma, Cancer

Phase 1

Update